| Budget Amount *help |
¥18,070,000 (Direct Cost: ¥13,900,000、Indirect Cost: ¥4,170,000)
Fiscal Year 2019: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2018: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
Fiscal Year 2017: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
|
|---|
| Outline of Final Research Achievements |
A: Development of a common tumor growth mechanism (RGM: Ras Gene Module) control method using an artificial gene switch method
A RTK (Receptor Tyrosine Kinase) control method was discovered. The oncogene fusion control method was discovered. We have developed a novel solid tumor stem cell / tumor marker control method.
B: Simulation drug development using supercomputer K: Development of p300-RUNX1 inhibitor; Candidate inhibitors were extracted from various cancers (prostate cancer DNPC), TNBC lung cancer, Kras mutant colon cancer and pancreatic cancer. Through the construction of an innovative anti-tumor concept that overcomes the resistance of molecular target drugs by A.B, we have achieved a fusion development method of human-school gene switch method and supercomputer simulation method.
|
